ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ACAD vs OGN // EV/EBITDA & P/E VALUATION

ACADIA Pharmaceuticals Inc. (NASDAQ) VS. Organon & Co. (NYSE) • 15-METRIC TALLY: ACAD 5 — OGN 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACAD VS. OGN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ACAD OGN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 91.70% 53.30% +38.40 ACAD /gross-margins <GO>
Return on Invested Capital (ROIC) 7.90% 24.90% -17.00 OGN /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 31.2x — — TIE /valuation <GO>
Free Cash Flow Yield 2.94% 14.83% -11.89 OGN /fcf-yield <GO>
Operating Margin 9.80% — — TIE /operating-margins <GO>
Net Profit Margin 36.50% 3.00% +33.50 ACAD /net-margins <GO>
Revenue Growth (YoY) 11.90% -2.90% +14.80 ACAD /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.43% -2.43 OGN /dividend-safety <GO>
Altman Z-Score & Debt/Equity 6.26 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 6/9 +1.00 ACAD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.5 67.8 -22.24 OGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 8.5x 18.0x -9.50 ACAD /forward-pe <GO>
Enterprise Scale & Market Cap $3.58B $3.63B -$49.6M OGN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ACAD REV OGN REV ACAD GROSS % OGN GROSS % ACAD FCF OGN FCF
FY 2025 $1.07B $6.22B 91.7% 53.3% $105.1M $538.0M
FY 2024 $957.8M $6.40B 91.5% 58.0% $157.2M $764.0M
FY 2023 $726.4M $6.26B — — $16.7M $799.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACAD // BETA —
OGN // BETA —